Table 2.
Relationships between S100A16 expression and clinic-opathological parameters
| Clinicopathological parameters | S100A16 expression
|
Total | P-value | |
|---|---|---|---|---|
| Positive (n=26) |
Negative (n=36) |
|||
| Age, years; n (%) | 0.613 | |||
| ≤60 | 11 (35.5) | 20 (64.5) | 31 | |
| >60 | 15 (44.1) | 19 (55.9) | 34 | |
| Sex; n (%) | 0.623 | |||
| Male | 13 (37.1) | 22 (62.9) | 35 | |
| Female | 13 (43.3) | 17 (56.7) | 30 | |
| Smoking habits; n (%) | 0.455 | |||
| Never smoked | 10 (34.5) | 19 (65.5) | 29 | |
| Smoker | 16 (44.4) | 20 (55.6) | 36 | |
| Tumor differentiation; n (%) | 1.000 | |||
| Well | 4 (44.4) | 5 (55.6) | 9 | |
| Moderately/poorly | 22 (39.3) | 34 (60.7) | 56 | |
| p-TNM stagea; n (%) | 1.000 | |||
| Stage IIA/IIB | 6 (37.5) | 10 (62.5) | 16 | |
| Stage IIIA | 20 (40.8) | 29 (59.2) | 49 | |
Note:
a
Each case was reassigned to a pathological stage on the basis of the IASLC Lung Cancer Staging Project (7th edition).
Abbreviations: IASLC, International Association for the Study of Lung Cancer; p-TNM, pathological TNM.